Product Profiles: Osteoporosis - Novel candidates offer the greatest potential


June 16, 2011
208 Pages - SKU: DFMN6424830
License type:
Table of Contents Related Reports Detailed Contents
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Product overview
MARKETED PRODUCT PROFILES
Fosamax/Fosamax Plus D (alendronate; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Fosamax
Clinical and commercial attractiveness
Actonel/Actonel with Calcium (risedronic acid; Sanofi/Warner Chilcott)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Actonel
Clinical and commercial attractiveness
Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Bonviva
Clinical and commercial attractiveness
Aclasta/Reclast (zoledronic acid; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Aclasta
Clinical and commercial attractiveness
Forteo (teriparatide; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Forteo
Clinical and commercial attractiveness
Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Evista (raloxifene; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Evista
Clinical and commercial attractiveness
Conbriza/Viviant (bazedoxifene; Pfizer/Almirall)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Protelos (strontium ranelate; Servier)
Drug profile
Development overview
SWOT analysis
Product positioning
Physician perception of Protelos
Clinical and commercial attractiveness
Edirol (eldecalcitol; Chugai/Taisho)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for osteoporosis
Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical)
Preotact (full-length PTH 1-84; NPS/Nycomed)
Miacalcic (calcitonin-salmon; Novartis)
Fortical (calcitonin-salmon; UniGene)
PIPELINE PRODUCT PROFILES
Odanacatib (MK0822; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
ZT-031 (hPTH1-31; Zelos Therapeutics)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
ZP-PTH (hPTH1-34; Zosano Pharma)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
BA058 (PTH peptide fragment; Radius)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
EX101 (alendronate; EffRx/Nycomed)
Drug profile
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Almerol (alendronate; Merrion)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Aprela (bazedoxifene with conjugated estrogens; Pfizer)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
SMC021 (salmon calcitonin; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Capsitonin (BN-002; Bone Medical)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
NBS101 (strontium malonate; Osteologix)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for osteoporosis
Fablyn (lasofoxifene; Pfizer/Ligand)
MK5442 (Merck & Co.)
Anti-sclerostin (AMG785; Amgen)
2MD/DP001 (vitamin D analog; Deltanoid Pharma)
San134 (glucagon-like peptide-2; Sanos Bioscience)
ACE-011 (activin inhibitor; Acceleron Pharma)
ViaDerm-hPTH (PTH peptide fragment; TransPharma/Eli Lilly)
CaPTHymone (PTH analog; Bone Medical)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Conferences attended
APPENDIX A - SURVEY INFORMATION
Physician research methodology
Physician sample breakdown
US
Japan
France
Germany
Italy
Spain
UK
Product Profiles (section 5)
APPENDIX B
Market definition
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Osteoporosis Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!